Etoposide Injection

DRUG10 trials

Sponsors

Taizhou Hospital, University of Maryland, Baltimore, Nanjing Leads Biolabs Co.,Ltd, BeBetter Med Inc, Beijing Chest Hospital, Capital Medical University

Conditions

Advanced Neuroendocrine CarcinomaExtensive-stage Small-cell Lung CancerLimited-stage Small-cell Lung CancerMalignant Solid TumorsRelapsed/Refractory Diffuse Large B-Cell LymphomaSmall Cell Lung CancerSmall Cell Lung Cancer Extensive StageSmall Cell Lung Carcinoma

Phase 1

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

SuspendedNCT05403723

University of Maryland, BaltimoreExtensive-stage Small-cell Lung Cancer

Start: 2026-06-30End: 2027-08-01Target: 50Updated: 2026-02-19

A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

RecruitingNCT06157827

Nanjing Leads Biolabs Co.,LtdAdvanced Neuroendocrine Carcinoma

Start: 2023-12-08End: 2027-03-28Target: 178Updated: 2026-03-12

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

BeBetter Med IncRelapsed/Refractory Diffuse Large B-Cell Lymphoma

Start: 2023-12-01End: 2025-11-05Target: 75Updated: 2023-12-11

Phase I Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer

RecruitingNCT07009457

Suzhou Suncadia Biopharmaceuticals Co., Ltd.Widespread Small Cell Lung Cancer

Start: 2025-06-16End: 2028-09-30Target: 48Updated: 2025-07-04

Phase 2

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

Taizhou HospitalSmall Cell Lung Carcinoma

Start: 2020-05-01End: 2023-03-31Target: 20Updated: 2020-04-28

PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC

Not yet recruitingNCT06375109

Beijing Chest Hospital, Capital Medical UniversityLimited-stage Small-cell Lung Cancer

Start: 2024-04-16End: 2029-04-15Target: 60Updated: 2024-04-19

A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

Not yet recruitingNCT06786312

Fujian Cancer HospitalSmall Cell Lung Cancer Extensive Stage

Start: 2025-01-25End: 2028-09-25Target: 34Updated: 2025-01-22

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

RecruitingNCT07268040

Shanghai Hengrui Pharmaceutical Co., Ltd.Malignant Solid Tumors

Start: 2025-12-23End: 2028-12-31Target: 400Updated: 2026-01-12

SKB500 Combinations in Patients With Small Cell Lung Cancer

RecruitingNCT07296809

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Small Cell Lung Cancer

Start: 2026-01-30End: 2029-12-31Target: 80Updated: 2026-04-02

Phase 3

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

RecruitingNCT06792253

BeBetter Med IncRelapsed/Refractory Diffuse Large B-Cell Lymphoma

Start: 2025-01-06End: 2029-06-30Target: 416Updated: 2025-01-24

Related Papers

Efficacy and safety of ifupinostat (BEBT-908) in combination with rituximab for relapsed/refractory diffuse large B-cell lymphoma: Results from an exploratory phase Ib study.

Journal of Clinical Oncology2025-05-281 citations

Assessment of efficacy of LBL-024, a novel and uniquely designed bispecific antibody against PD-L1 and 4-1BB, combined with etoposide/platinum-based chemotherapy in treatment-naive advanced extrapulmonary neuroendocrine carcinoma (EP-NEC): A multicenter phase Ib/II trial.

Journal of Clinical Oncology2025-05-28

468 A phase 2 study of toripalimab plus anlotinib as maintenance therapy in extensive-stage small cell lung cancer

Regular and Young Investigator Award Abstracts2021-11-011 citations

Abstract CT232: A phase II study of toripalimab plus anlotinib as maintenance therapy in extensive-stage small cell lung cancer

Cancer Research2021-07-01